Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Net Cash Flow (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Net Cash Flow for 4 consecutive years, with $153.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow rose 151.65% to $153.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $72.1 million, a 168.15% increase, with the full-year FY2025 number at $72.1 million, up 168.15% from a year prior.
  • Net Cash Flow was $153.8 million for Q4 2025 at Day One Biopharmaceuticals, up from $7.7 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $183.1 million in Q3 2024 to a low of -$297.8 million in Q4 2024.
  • A 4-year average of -$5.5 million and a median of -$4.1 million in 2023 define the central range for Net Cash Flow.
  • Biggest YoY gain for Net Cash Flow was 252.43% in 2024; the steepest drop was 2764.81% in 2024.
  • Day One Biopharmaceuticals' Net Cash Flow stood at -$35.6 million in 2022, then surged by 70.8% to -$10.4 million in 2023, then plummeted by 2764.81% to -$297.8 million in 2024, then soared by 151.65% to $153.8 million in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Net Cash Flow are $153.8 million (Q4 2025), $7.7 million (Q3 2025), and $2.3 million (Q2 2025).